Lirentelimab

Tax included
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis.
MedChemExpress 
HY-P99371

Data sheet

Size
Multiple sizes
Reactivity
Apoptosis
Application
COVID-19-immunoregulation
CAS
2283348-97-8